Evidence map›Paper›PMID 34483209›Full record

ArticleInternal medicine (Tokyo, Japan)2022

Persistent Hypoglycemia Induced by Long-acting Insulin Degludec.

Yukino Katakura, Fuminori Tatsumi, Takashi Kusano, Masashi Shimoda, Kenji Kohara, Tomohiko Kimura, Atsushi Obata, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku and 1 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.1field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Long-lasting hypoglycemia through insulin degludec during acute kidney injury after diabetic ketoacidosis: A case report.Clinical pediatric endocrinology : case reports and clinical investigations : official journal of the Japanese Society for Pediatric Endocrinology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Yukino KatakuraDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Fuminori TatsumiDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Takashi KusanoDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Masashi ShimodaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Kenji KoharaDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Tomohiko KimuraDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Atsushi ObataDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Shuhei NakanishiDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Tomoatsu MuneDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Kohei KakuDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Hideaki KanetoDepartment of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Japan.
Kawasaki Medical School Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 58-year-old Japanese man was brought to the emergency room due to disturbance of consciousness. He regained consciousness on the day of admission and started taking hospital meals, but he needed intravenous glucose administration for eight days. The total amount of glucose administration was 4,464 g. It took over three weeks for exogenous insulin to be almost undetectable. While degludec binds to albumin and exerts glucose-lowering effects for a long time, the above-mentioned period of three weeks was consistent with the half-life of albumin. Hypoglycemia induced by massive dose of insulin degludec is persistent and prominent.

Indexed as

Diabetes Mellitus, Type 1Diabetes Mellitus, Type 2HypoglycemiaBlood GlucoseGlycated HemoglobinHumansHypoglycemic AgentsInsulin GlargineInsulin, Long-ActingMaleMiddle AgedBlood GlucoseGlycated HemoglobinHypoglycemic Agentsinsulin degludecInsulin GlargineInsulin, Long-Actinga pitfalldiabetes careinsulin degludecinsulin therapysevere hypoglycemia

Identifiers

PMID34483209
PMCPMC8987256
OpenAlexW3198349672

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.